Načítá se...
Review article: systemic treatment of hepatocellular carcinoma
BACKGROUND: The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma. Since then many drugs failed in the...
Uloženo v:
| Vydáno v: | Aliment Pharmacol Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6120553/ https://ncbi.nlm.nih.gov/pubmed/30039640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14913 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|